Results 101 to 110 of about 59,490 (296)

Evaluating the Real‐World Safety of Ravulizumab in Generalized Myasthenia Gravis: Insights From a Detailed Analysis of FAERS Data

Journal of Clinical Pharmacy and Therapeutics, Volume 2026, Issue 1, 2026.
Background Ravulizumab represents the inaugural long‐acting complement C5 inhibitor that has received approval in various countries around the globe for individuals diagnosed with generalized myasthenia gravis (gMG) who are positive for anti‐acetylcholine receptor antibodies.
Yakun Wang, Qian Guo, Jiayu Bai, Jiaqi Shi, Ziquan Yang, Hongda Liu   +5 more
wiley   +1 more source

The Hemolytic Uremic Syndrome

Pediatric Clinics of North America, 1995
HUS is the most common cause of acute renal failure in infants and young children and follows a diarrheal prodrome about 90% of the time. Persuasive evidence shows that virtually all of postdiarrheal cases are caused by EHEC infections, and that the great majority of cases in the United States are caused by the EHEC serotype O157:H7.
Remuzzi, Giuseppe, Ruggenenti, Piero
openaire   +5 more sources

Mixture of Origanum heracleoticum L. and Satureja montana L. Essential Oils as Natural Antimicrobial Agents for Fresh Meat Preservation

Journal of Food Processing and Preservation, Volume 2026, Issue 1, 2026.
The aim of this study was to investigate the antimicrobial potential of individual EOs of Origanum vulgare L., Origanum heracleoticum L., Satureja montana L., and Tagetes patula L. (extracted from organically grown plants), as well as a mixture containing O. heracleoticum L. and S.
Sunčica Kocić-Tanackov, Darko Lazarević, Snežana Kravić, Vladimir Tomović, Branislav Šojić, Sandra Bulut, Jelena Živančev, Igor Antić, Dragana Mladenović, Danijela Bursać Kovačević, Hrvoje Pavlović, Essam Hebishy   +11 more
wiley   +1 more source

Eculizumab for Gemcitabine-Induced Hemolytic Uremic Syndrome: A Novel Therapy for an Emerging Condition [PDF]

, 2015
Introduction Atypical hemolytic uremic syndrome (aHUS), a thrombotic microangiopathy (TMA), is a disease characterized by hemolytic anemia, thrombocytopenia, and renal impairment. Gemcitabine, a commonly used chemotherapy, is emerging as a cause of aHUS.
Karkowsky, MD, Raphael, Parikh, MD, Kinjal   +1 more
core   +2 more sources

Multiple Myeloma as the Underlying Cause of Thrombotic Microangiopathy Leading to Acute Kidney Injury: Revisiting a Very Rare Entity

Journal of Investigative Medicine High Impact Case Reports, 2017
Thrombotic microangiopathy (TMA) describes a pathological process of microvascular thrombosis, consumptive thrombocytopenia, and microangiopathic hemolytic anemia, leading to end-organ ischemia and infarction, affecting particularly the kidney and brain.
Savneek Chugh MD, Asim Kichloo MD, Firas Jafri MD, Liga Yusvirazi MD, Robert Lerner MD   +4 more
doaj   +1 more source

Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report

Journal of Medical Case Reports, 2017
Background The incidence of gemcitabine-induced hemolytic uremic syndrome has already been described in adults. Several approaches have been employed in the treatment of gemcitabine-induced hemolytic uremic syndrome with different outcomes.
Ludovica Facchini, Maurizio Lucchesi, Alessia Stival, Rosa Maria Roperto, Francesca Melosi, Marco Materassi, Silvia Farina, Veronica Tintori, Maurizio de Martino, Iacopo Sardi   +9 more
doaj   +1 more source

Dexamethasone Rescues Neurovascular Unit Integrity from Cell Damage Caused by Systemic Administration of Shiga Toxin 2 and Lipopolysaccharide in Mice Motor Cortex [PDF]

, 2013
Shiga toxin 2 (Stx2)-producing Escherichia coli (STEC) causes hemorrhagic colitis and hemolytic uremic syndrome (HUS) that can lead to fatal encephalopathies.
Cangelosi, Adriana, Cejudo, Maria Laura, Geoghegan, Patricia, Goldstein Raij, Jorge, Jacobsen, Mariana Elena, Pinto, Alipio, Tironi-Farinati, Carla   +6 more
core   +3 more sources

Update of the list of qualified presumption of safety (QPS) recommended microbiological agents intentionally added to food or feed as notified to EFSA 23: Suitability of taxonomic units notified to EFSA until September 2025

EFSA Journal, Volume 24, Issue 1, January 2026.
Abstract The qualified presumption of safety (QPS) process was developed to provide a harmonised safety assessment approach to support EFSA Scientific Panels and Units. The QPS approach assesses the taxonomic identity, body of relevant knowledge and safety of microorganisms intentionally added to the food and feed chain.
EFSA Panel on Biological Hazards (BIOHAZ), Ana Allende, Avelino Alvarez‐Ordóñez, Valeria Bortolaia, Sara Bover‐Cid, Alessandra De Cesare, Wietske Dohmen, Laurent Guillier, Liesbeth Jacxsens, Maarten Nauta, Lapo Mughini‐Gras, Jakob Ottoson, Luisa Peixe, Fernando Perez‐Rodriguez, Panagiotis Skandamis, Elisabetta Suffredini, Marianne Chemaly, Pier Sandro Cocconcelli, Pablo Salvador Fernández Escámez, Miguel Prieto Maradona, Amparo Querol, Lolke Sijtsma, Juan Evaristo Suarez, Ingvar Sundh, Fulvio Barizzone, Justine Dastouet, Nadya Doyle, Sandra Correia, Lieve Herman   +28 more
wiley   +1 more source

Nicotinamide Attenuates Complement and Coagulation Pathways and Resultant Renal Fibrosis

The FASEB Journal, Volume 39, Issue 23, 15 December 2025.
The coagulation and complement cascades were elevated in the pathogenesis of chronic kidney disease (CKD) and may contribute to both kidney injury and cardiovascular risk. These excessive signals and the associated innate immune responses were suppressed by the NAD+ precursor nicotinamide (NAM).
Saori Kin, Yuji Oe, Taku Obara, Emiko Sato, Nobuyuki Takahashi, Mariko Miyazaki, Tetsuhiro Tanaka   +6 more
wiley   +1 more source

Safety and efficacy of eculizumab in adult and pediatric patients with aHUS, with or without baseline dialysis [PDF]

, 2015
C
Hourmant, Maryvonne, Kincaid, John F, Legendre, Christophe M, Menne, Jan, van de Kar, Nicole CAJ, Vande Walle, Johan   +5 more
core   +1 more source